Drugs / Metapex
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT06925490 Comparator | Jun 2025 → Sep 2026 overdue | pulpitis | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT04336709 Comparator | Apr 2020 → Apr 2021 | chronic apical periodontitis | Aga Khan University | Completed | No outcome recorded |
| Phase 3 | NCT05657132 Comparator | Aug 2021 → Dec 2022 | primary bacterial infectious disease | Nahda University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Metapex | “Calcium hydroxide iodoform paste (Metapex) as an intracanal medicament” NCT05657132 ↗ |
| Action | Inhibit | “in reducing the number of enterococcus faecalis” NCT05657132 ↗ |